Hepa Thera Announces First CHB Patient Dosed in HT-101 (Its siRNA Product) Phase 1b Part
This week Suzhou Hepa Thera Biotech Co., Ltd enrolled the first chronic hepatitis B patient in Beijing Friendship Hospital,Capital Medical University for its siRNA product, HT-101. This progress marks HT-101 entering Phase 1b trial, and the trial will be expected to end in the first half year of 2024.
Meanwhile, another new product, HT-102 which is the neutralizing antibody against HBsAg, was also approved for its IND application in this month, and will initiate phase I in the early June.
Using the method of combo-treatment of siRNA and Neutralizing antibody, Hepa thera will explore the possibility to achieve the functional cure of CHB patients after the completion of the Phase 1 clinical trials of HT101 and HT102. It shall be noted here that Hepa thera is one of few companies which have the combo-treatment regime, and will hold great promising hope for the patients with chronic hepatitis.
About Hepa Thera
Established in May 2021, Suzhou Hepa Thera Biopharmaceutical Co., Ltd is a biotechnology company hatched by the New Drug Fund of Health Capital, specialized in the development of innovative drugs for liver disease treatment. Based on RNA interference, antibody, fusion protein, gene editing and other technologies, Hepa Thera addresses the unmet needs in the field of liver disease treatment including hepatitis B, nonalcoholic fatty liver disease, liver fibrosis, liver cirrhosis, independent immune liver disease; it develops products in cooperation with universities, scientific research institutes and pharmaceutical companies by means of joint development, R&D contracts and licensed introduction and other modes, and is expected to develop into an innovative enterprise putting a dent in the field of liver disease treatment in China.Established in May 2021, Suzhou Hepa Thera Biotech Co., Ltd is a biotech company incubated by the New Drug Fund of Fosun Health Capital, specialized in the development of innovative drugs for liver disease treatment. Based on RNA interference, antibody, fusion protein, gene editing and other technologies, Hepa Thera addresses the unmet needs in the field of liver disease treatment including hepatitis B, nonalcoholic fatty liver disease, liver fibrosis, liver cirrhosis, independent immune liver disease; it develops products in cooperation with universities, scientific research institutes and pharmaceutical companies by means of joint development, R&D contracts and licensed introduction and other modes, and is expected to develop into an innovative enterprise putting a dent in the field of liver disease treatment in China.
Business cooperation：Yajun He +86-13716194562 bd@hepathera.com
